Since the BPC-157 + TB-500 stack is probably the most discussed combination on this board, let's consolidate the practical details in one place.
Why these two are commonly combined:
BPC-157 and TB-500 work through different mechanisms. BPC-157 modulates nitric oxide pathways, interacts with the dopamine system, and upregulates growth factors including VEGF, FGF, and EGF. TB-500 promotes angiogenesis through actin upregulation and cell migration. The theory is that they're complementary — BPC-157 kickstarts the repair signaling while TB-500 provides the structural support for new tissue formation.
Standard combination protocol:
BPC-157: 250-500mcg twice daily (morning and evening). TB-500: 2-2.5mg twice weekly (e.g., Monday and Thursday).
Some researchers prefer to load TB-500 higher for the first 2-3 weeks (2.5mg twice weekly) then drop to maintenance (2.5mg once weekly) while keeping BPC-157 consistent throughout.
Timing — same injection or separate?
They can be injected at the same time. Many researchers draw both into the same syringe for convenience. There is no documented interaction that would make co-injection problematic. However, some prefer separate injections to track individual responses, especially when starting both for the first time.
Injection site — local vs systemic:
This is the most debated topic. BPC-157 is often injected subcutaneously as close to the target area as possible. The rationale is local concentration at the injury site. Community consensus generally favors local injection for BPC-157 when targeting a specific area.
TB-500 is considered more systemically acting due to its mechanism. It doesn't need to be injected locally — subcutaneous injection in the abdomen is the most common approach. TB-500 is a larger molecule that distributes systemically regardless of injection site.
Practical recommendation from community experience:
If targeting a specific injury (knee, shoulder, elbow): Inject BPC-157 subcutaneously near the affected area. Inject TB-500 in the abdomen or thigh — wherever is convenient.
If running for general recovery or systemic benefit: Both can be injected in the abdomen or wherever you prefer. Local injection is less important when there's no specific target.
Duration:
Most community protocols run 8-12 weeks. Some researchers run BPC-157 alone for longer maintenance after completing the TB-500 portion, since BPC-157 is generally cheaper and easier to source.
What to track:
Range of motion measurements, pain levels (use a 1-10 scale consistently), functional tests (can you do X movement now that you couldn't before?), and any side effects. The more specific your documentation, the more useful it is for yourself and the community.